Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
2006 1
2008 1
2009 1
2010 3
2011 4
2012 5
2013 12
2014 9
2015 15
2016 22
2017 27
2018 18
2019 32
2020 24
2021 30
2022 11
2023 10

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27634982

201 results

Results by year

Filters applied: . Clear all
Page 1
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215
68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia.
El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R, Millo C, Chen CC, Kebebew E, Collins MT. El-Maouche D, et al. J Clin Endocrinol Metab. 2016 Oct;101(10):3575-3581. doi: 10.1210/jc.2016-2052. Epub 2016 Aug 17. J Clin Endocrinol Metab. 2016. PMID: 27533306 Free PMC article.
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors.
Parghane RV, Talole S, Basu S. Parghane RV, et al. World J Nucl Med. 2019 Apr-Jun;18(2):160-170. doi: 10.4103/wjnm.WJNM_39_18. World J Nucl Med. 2019. PMID: 31040748 Free PMC article.
Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
Zemczak A, Kołodziej M, Gut P, Królicki L, Kos-Kudła B, Kamiński G, Ruchała M, Pawlak D, Kunikowska J. Zemczak A, et al. Endokrynol Pol. 2020;71(3):240-248. doi: 10.5603/EP.a2020.0014. Epub 2020 Apr 15. Endokrynol Pol. 2020. PMID: 32293704 Free article.
201 results